Sign in Subscribe
Hi, Biotech
The science getting funded, explained.

Latest

24
Oct
The Q3 2026 biotech funding tracker: a rebound that only the rich feel

The Q3 2026 biotech funding tracker: a rebound that only the rich feel

Biotech venture dollars are up sharply — and almost all of the money went to a handful of AI-shaped names. The gap beneath the megadeals is the real story.
2 min read
24
Oct
Dengue's hard year: how 2026 broke the vaccine field's momentum — and what happens now

Dengue's hard year: how 2026 broke the vaccine field's momentum — and what happens now

Brazil suspended the world's first single-dose dengue vaccine after two deaths under investigation. Sanofi is exiting the market entirely. The US is about to have zero licensed dengue vaccines. Inside the most turbulent year in flavivirus history.
2 min read
23
Oct
The archive in the attic: what this domain's first tenant knew about dengue twenty years early

The archive in the attic: what this domain's first tenant knew about dengue twenty years early

Before it was a newsroom, hibiotech.com was the home of a Hawaiian dengue vaccine developer. Its press archive — 59 releases spanning 2002 to 2016 — reads like a rough draft of today's flavivirus headlines. We're restoring it.
2 min read
23
Oct
Qdenga's long shadow: the world's most consequential vaccine that America won't touch

Qdenga's long shadow: the world's most consequential vaccine that America won't touch

Takeda's two-dose shot is carrying national programs on four continents — while staying unapproved in the country that helped invent modern vaccinology. Why the gap is unlikely to close.
2 min read
22
Oct
mRNA's second act arrives, and it looks like a flu shot

mRNA's second act arrives, and it looks like a flu shot

The FDA has approved the first mRNA influenza vaccine. The combo COVID-plus-flu jab data is next, and a bird-flu pandemic trial is already running. The technology's post-COVID chapter finally has product in it.
2 min read
22
Oct
Why there's still no human West Nile vaccine — and the candidates closest to changing that

Why there's still no human West Nile vaccine — and the candidates closest to changing that

A quarter-century after the virus reached New York, horses have a vaccine and humans don't. The tracker of what's actually in trials.
2 min read
21
Oct
Why Big Pharma is licensing earlier (and paying more)

Why Big Pharma is licensing earlier (and paying more)

Seven in ten recent deals happened at preclinical or phase 1 — capturing three quarters of upfront cash. The patent cliff has turned early-stage biology into a seller's market.
2 min read
21
Oct
The first real verdicts are in for AI-discovered drugs

The first real verdicts are in for AI-discovered drugs

No AI-designed molecule has full FDA approval yet. But the first AI-native candidate has reached phase 3, the mid-stage data has started arriving, and the question has changed from 'how fast?' to 'do they work?'
2 min read
20
Oct
Fill-finish: the bottleneck nobody wants to build

Fill-finish: the bottleneck nobody wants to build

Lonza says the CDMO world doesn't have the capacity. Demand is booked years ahead. Inside the least glamorous constraint in biotech.
2 min read
19
Oct
The platform premium, audited: what a $200M Series B actually buys

The platform premium, audited: what a $200M Series B actually buys

Isomorphic raised $2.1 billion without a marketed product. AI-native biotechs routinely clear nine figures pre-clinic. An audit of what the money purchases — and what evidence would justify it.
2 min read